Is Nerve Electrophysiology a Robust Primary Endpoint in Clinical Trials of Treatments for Diabetic Peripheral Neuropathy?

There is currently no FDA-approved disease-modifying therapy for diabetic peripheral neuropathy (DPN). Nerve conduction velocity (NCV) is an established primary endpoint of disease-modifying therapies in DPN and clinical trials have been powered with an assumed decline of 0.5 m/s/year. This paper so...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Dalal Y. Al-Bazz, Andrew J. Nelson, Jamie Burgess, Ioannis N. Petropoulos, Jael Nizza, Anne Marshall, Emily Brown, Daniel J. Cuthbertson, Andrew G. Marshall, Rayaz A. Malik, Uazman Alam
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2022-03-01
Saila:	Diagnostics
Gaiak:	nerve electrophysiology peripheral neuropathy diabetes
Sarrera elektronikoa:	https://www.mdpi.com/2075-4418/12/3/731
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!